Skip to main content
. Author manuscript; available in PMC: 2020 Dec 1.
Published in final edited form as: Clin Cancer Res. 2020 Feb 21;26(11):2535–2545. doi: 10.1158/1078-0432.CCR-19-3906

Figure 5. Clinical Activity of Dual ALK/MET TKIs in MET-Driven Resistance.

Figure 5.

(A) Timeline of treatments and biopsies for MGH915. NGS: next-generation sequencing; n.d.: not performed; v1: EML4-ALK variant 1, or fusion of exon 13 of EML4 to exon 20 of ALK; R: right; LN: lymph node; FISH: fluorescence in-situ hybridization (B) FISH images from serial biopsies demonstrate progressive increase in MET copy number. LN: lymph node; MET/CEP7: ratio of MET to centromere 7 probe. (C) CT scans depicting radiologic response to combined lorlatinib and crizotinib, with decrease in pleural fluid and lung mass (red arrow, top panels) and decrease in right axillary node (bottom panels, red arrow). The patient later relapsed at these same sites due to resistance.